Expert Interview
Discussing the potential of Neurocrine Bio's recently FDA approved INGREZZA (valbenazine) for the treatment of Chorea associated with Huntington's Disease
Ticker(s): NBIXInstitution: Mayo Clinic
- Professor of Neurology at Mayo Clinic College of Medicine.
- Manages ~40 patients with Huntington's Disease per year.
- Research interests in Parkinson's disease, Myoclonus, Chorea, Electroencephalography (EEG), Huntington's disease, and Electrophysiology of movement disorders; his lab is developing and validating electrophysiological biomarkers for the cognitive decline in Parkinson's disease.
How many patients with Huntington's disease do you currently treat?
Added By: chanell_adminAre you familiar with the results from the KINECT Phase 3 study which the FDA based the approval of INGREZZA from
Added By: chanell_adminWhat other movement disorders do you think the drug may have possibilities to treat?
Added By: bhagatnWhat do you see as the share of the prescriptions you expect Ingrezza to have in different markets by 2030?
Added By: bhagatnAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
